Tandem Diabetes CareTNDM
About: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Employees: 2,400
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,272% more call options, than puts
Call options by funds: $145M | Put options by funds: $10.5M
150% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 5 (+3) [Q3]
26% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 46
4% more funds holding
Funds holding: 315 [Q2] → 327 (+12) [Q3]
3% more capital invested
Capital invested by funds: $3.01B [Q2] → $3.1B (+$91.5M) [Q3]
6% less repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 116
3.94% less ownership
Funds ownership: 115.51% [Q2] → 111.57% (-3.94%) [Q3]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Citigroup Joanne Wuensch 57% 1-year accuracy 27 / 47 met price target | 35%upside $50 | Buy Maintained | 11 Dec 2024 |
Morgan Stanley Patrick Wood 55% 1-year accuracy 6 / 11 met price target | 22%upside $45 | Overweight Upgraded | 2 Dec 2024 |
Barclays Matt Miksic 64% 1-year accuracy 23 / 36 met price target | 62%upside $60 | Overweight Maintained | 8 Nov 2024 |
Canaccord Genuity William Plovanic 54% 1-year accuracy 25 / 46 met price target | 51%upside $56 | Buy Maintained | 7 Nov 2024 |
Baird Jeff Johnson 23% 1-year accuracy 3 / 13 met price target | 0%upside $37 | Neutral Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 3 articles about TNDM published over the past 30 days